First oral monotherapy for patients with paroxysmal nocturnal haemoglobinuria

View source ↗

Summary

EMA has recommended EU marketing authorization for Fabhalta (iptacopan), an oral monotherapy for adults with paroxysmal nocturnal haemoglobinuria and haemolytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Haemoglobinuria

Drugs mentioned

• FABHALTA (IPTACOPAN)

Snippet

EMA has recommended granting a marketing authorisation in the European Union (EU) for Fabhalta (iptacopan), an oral treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.